DAAs and long-term clinical outcome in hepatitis C: the panacea for all diseases still does not exist

Am J Gastroenterol. 2018 Aug;113(8):1251. doi: 10.1038/s41395-018-0062-3.

Authors

Alessandro Perrella^{1

1}, Luca Rinaldi¹, Alfonso Galeota-Lanza¹, Antonio Izzi¹

Affiliation

¹ VII Department of Infectious Disease and Immunology, Ospedali dei Colli P. O. D. Cotugno, Naples, Italy. Liver Unit, King's College medical School University, London, UK. Gastroenterology Unit, Università degli Studi della Campania "Luigi Vanvitelli", Naples, Italy. Hepatology Unit, AORN Hospital A. Cardarelli, Naples, Italy. I Division Infectious Disease, Ospedali dei Colli P. O. D. Cotugno, Naples, Italy.

PMID: 29686274
DOI: 10.1038/s41395-018-0062-3

No abstract available

Publication types

Letter
Comment

MeSH terms

Antiviral Agents*
Hepacivirus
Hepatitis C*
Hepatitis C, Chronic*
Humans

Substances

Antiviral Agents